AMPK-JAK2/STAT3 Axis in M1 Macrophage Polarization and Obesity-Related Asthma

Study Background and Research Question

Obesity-related asthma is an increasingly prevalent phenotype characterized by persistent, nonallergic inflammation and poor response to standard treatments. Unlike classic allergic asthma, this form is marked by corticosteroid resistance, low eosinophil counts, and pronounced metabolic dysregulation. Recent epidemiological data suggest that up to 60% of severe asthma cases are comorbid with obesity, making this a pressing clinical challenge. Macrophages, particularly their polarization towards pro-inflammatory (M1) or anti-inflammatory (M2) states, are central to the pathophysiology of airway inflammation. However, the molecular mechanisms linking metabolic dysfunction, macrophage polarization, and airway inflammation remain inadequately defined. The reference study (Lei et al., 2024) addresses the specific role of AMPK—an energy sensor kinase—in regulating M1 macrophage polarization and airway inflammation in the context of obesity-related asthma, with a focus on the JAK2/STAT3 signaling pathway.

Key Innovation from the Reference Study

The pivotal innovation of this work lies in demonstrating that AMPK acts as a negative regulator of M1 macrophage polarization via the JAK2/STAT3 axis in obesity-related asthma. While AMPK's anti-inflammatory functions and its role in cellular energy balance are well established, this study is among the first to delineate how downregulation of AMPK in obese asthmatic lung tissue specifically enhances M1 macrophage polarization, driving airway inflammation. Furthermore, exogenous activation of AMPK was shown to reduce M1 polarization and inflammation, suggesting a direct mechanistic link and potential therapeutic target for this asthma subtype.

Methods and Experimental Design Insights

The research employed a comprehensive set of in vivo and in vitro models. Obesity-related asthma was induced in mice, and lung tissues were analyzed using hematoxylin-eosin (HE), periodic acid-Schiff (PAS), and Masson’s trichrome staining to assess inflammation and airway remodeling. Immunohistochemical and immunofluorescence assays were utilized to evaluate macrophage polarization markers (e.g., CD86 for M1, CD206 for M2). In parallel, the RAW264.7 macrophage cell line was stimulated with lipopolysaccharide (LPS) to model inflammatory activation in vitro. Key mechanistic interventions included exogenous AMPK activation, followed by assessment of JAK2/STAT3 pathway components using Western blot, qRT-PCR, and ELISA for inflammatory cytokines (IL-6, TNF-α, IL-1β, MCP-1).

Protocol Parameters

• Obesity-related asthma model induction: High-fat diet in mice followed by allergen challenge, as detailed in the reference study.
• Macrophage polarization assessment: Immunohistochemistry and immunofluorescence for CD86 (M1) and CD206 (M2) markers in lung tissue sections.
• In vitro LPS stimulation: RAW264.7 cells treated with LPS (typically 100 ng/mL) to induce M1 polarization.
• AMPK activation: Exogenous application of AMPK activators; dosing and timing should be calibrated based on cell type and experimental goals, as performed in the reference study.
• JAK2/STAT3 pathway interrogation: Western blot detection of phosphorylated and total JAK2/STAT3 proteins following AMPK modulation.
• Inflammatory cytokine quantification: ELISA for secreted IL-6, TNF-α, IL-1β, and MCP-1 in cell supernatants and lung homogenates.

Core Findings and Why They Matter

The central findings are as follows:

• M1 macrophage polarization dominates in obese asthmatic lung tissue, coinciding with suppressed AMPK expression.
• AMPK activation reverses M1 polarization and decreases airway inflammation, both in vivo and in vitro. Notably, this effect is mediated through modulation of the JAK2/STAT3 signaling pathway.
• Inflammatory cytokine production (IL-6, TNF-α, IL-1β, MCP-1) is significantly reduced by AMPK activation, confirming its anti-inflammatory role.

These results support a model in which AMPK serves as a metabolic checkpoint, restraining pro-inflammatory macrophage activation via JAK2/STAT3 inhibition. This is particularly relevant for obesity-related asthma, where metabolic and inflammatory pathways converge to drive disease severity. Targeting AMPK could thus reprogram macrophage function and attenuate airway inflammation where standard therapies are insufficient (Lei et al., 2024).

Comparison with Existing Internal Articles

The dual role of AMPK in both metabolic regulation and inflammation is echoed in several internal resources. For example, the article "Decoding AMPK and BMP Pathways: Strategic Insights for Translational Research" explores how Dorsomorphin (Compound C) enables researchers to dissect the AMPK pathway in models of autophagy, muscle atrophy, and iron metabolism modulation. These resources emphasize the use of small-molecule inhibitors and activators to interrogate AMPK signaling, which aligns with the methodology in the reference paper. Additionally, "Dorsomorphin (Compound C) for Reliable AMPK and BMP Pathway Dissection" provides protocol guidance for pathway inhibition in metabolic and differentiation studies, highlighting the importance of precise pathway modulation for reproducible mechanistic insight. While these internal articles focus on the broader applications of AMPK and BMP signaling inhibitors, the reference study narrows the focus to airway inflammation and macrophage polarization in obesity-related asthma, thus filling a specific gap in translational immunometabolism.

Limitations and Transferability

While the mechanistic findings are robust, several limitations must be acknowledged. First, the study relies predominantly on murine models and immortalized cell lines, which, while informative, may not fully recapitulate the cellular complexity or microenvironmental cues present in human disease. The interventions target AMPK broadly, and off-target effects—particularly in metabolic tissues—cannot be excluded. Additionally, the interplay between AMPK and other signaling pathways beyond JAK2/STAT3 (e.g., NF-κB, BMP4-induced SMAD phosphorylation inhibition) warrants further investigation. Caution is advised when extrapolating these findings to clinical populations, especially considering heterogeneity in asthma phenotypes and comorbid metabolic conditions.

Research Support Resources

For researchers aiming to dissect the AMPK pathway in macrophage polarization, autophagy regulation, or related metabolic-inflammation models, the use of selective pharmacological tools is essential. Dorsomorphin (Compound C) (SKU B3252) from APExBIO is a well-characterized, ATP-competitive AMPK inhibitor with proven selectivity and is widely used in studies requiring inhibition of AMPK activity in hepatocytes, immune cells, and cancer models. Its dual action on AMPK and BMP signaling, as described in both product documentation and internal protocols, makes it a valuable reagent for mechanistic studies like those described here. For best practices and detailed application scenarios, see the internal protocols linked above. Dorsomorphin should be dissolved in DMSO and used promptly after preparation, in accordance with manufacturer recommendations.